Review Article| Volume 48, ISSUE 10, P1119-1123, October 2016

Download started.


Treatment sequence of synchronously (liver) metastasized colon cancer


      No standards for staging, systemic therapy or the timing of an operation are defined for patients newly diagnosed with synchronous metastases and a primary in the colon. An expert group of radiologists, medical, radiation and surgical oncologists therefore came together to discuss staging and treatment sequence for these patients and came up with a recommendation based on current evidence of potential therapeutic options. The discussion was organized to debate recommendations centred on 5 topics and therefore the position paper is built upon these titles and their subtitles.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Nordlinger B.
        • Guiguet M.
        • Vaillant J.
        • et al.
        Surgical resection of colorectal carcinoma metastases to the liver.
        Cancer. 1996; 77: 1254-1262
        • Zech C.J.
        • Korpraphong P.
        • Huppertz A.
        • et al.
        Randomized multicentre trial of gadoxetic acid-enhanced MRIversus conventional MRI or CT in the staging of colorectal cancer liver metastases.
        British Journal of Surgery. 2014; 101: 613-621
        • Brush J.
        • Boyd K.
        • Chappell F.
        • et al.
        The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.
        Health Technology Assessment. 2011; 15: 192
        • Ihnát P.
        • Vávra P.
        • Zonča P.
        Treatment strategies for colorectal carcinoma with synchronous liver metastases: which way to go?.
        World Journal of Gastroenterology. 2015; 21: 7014-7021
        • van de Velde C.J.H.
        • Boelens P.G.
        • Tanis P.J.
        • et al.
        Experts reviews of the multidisciplinary consensus conference colon and rectal cancer 2012: science, opinions and experiences from the experts of surgery.
        European Journal of Surgical Oncology (EJSO). 2014; 40: 454-468
        • Schindl M.J.
        • Redhead D.N.
        • Fearon K.C.H.
        • et al.
        The value of residual liver volume as a predictor of hepatic dysfunction and infection after major liver resection.
        Gut. 2005; 54: 289-296
        • Nordlinger B.
        • Van Cutsem E.
        • Gruenberger T.
        • et al.
        Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel.
        Annals of Oncology. 2009; 20: 985-992
        • Van Cutsem E.
        • Cervantes A.
        • Nordlinger B.
        • Arnold D.
        Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
        Annals of Oncology. 2014; 25 (iii1–9)
        • Lan Y.-T.
        • Jiang J.-K.
        • Chang S.-C.
        • et al.
        Improved outcomes of colorectal cancer patients with liver metastases in the era of the multidisciplinary teams.
        International Journal of Colorectal Disease. 2016; 31: 403-411
        • Fong Y.
        • Fortner J.
        • Sun R.
        • et al.
        Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases.
        Annals of Surgery. 1999; 230: 309-321
        • Aaronson N.K.
        • Ahmedzai S.
        • Bergman B.
        • et al.
        The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.
        Journal of the National Cancer Institute. 1993; 85: 365-376
        • Quan D.
        • Gallinger S.
        • Nhan C.
        • et al.
        The role of liver resection for colorectal cancer metastases in an era of multimodality treatment: A systematic review.
        Surgery. 2012; 151: 860-870
        • McCahill L.E.
        • Yothers G.
        • Sharif S.
        • et al.
        Primary mFOLFOX6 Plus Bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP Trial C-10.
        Journal of Clinical Oncology. 2012; 30: 3223-3228
        • Venderbosch S.
        • de Wilt J.H.
        • Teerenstra S.
        • et al.
        Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature.
        Annals of Surgical Oncology. 2011; 18: 3252-3260
        • ’t Lam-Boer J.
        • Mol L.
        • Verhoef C.
        • et al.
        The CAIRO4 study: the role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer – a randomized phase III study of the Dutch Colorectal Cancer Group (DCCG).
        BMC Cancer. 2014; 14: 741
        • Rahbari N.N.
        • Lordick F.
        • Fink C.
        • et al.
        Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS – a randomised controlled multicentre trial (ISRCTN30964555).
        BMC Cancer. 2012; 12: 142
        • Lamazza A.
        • Fiori E.
        • Schillaci A.
        • et al.
        Self-expandable metallic stents in patients with stage IV obstructing colorectal cancer.
        World Journal of Surgery. 2012; 36: 2931-2936
        • Manfredi S.
        • Sabbagh C.
        • Vanbiervliet G.
        • et al.
        Place of colorectal stents in therapeutic management of malignant large bowel obstructions.
        Endoscopy. 2014; 46: 546-552
        • van Hooft J.E.
        • van Halsema E.E.
        • Vanbiervliet G.
        • et al.
        Self-expandable metal stents for obstructing colonic and extracolonic cancer: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline.
        Gastrointestinal Endoscopy. 2014; 80 (747–761.e775)
        • Kabbinavar F.F.
        • Flynn P.J.
        • Kozloff M.
        • et al.
        Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study.
        European Journal of Cancer. 2012; 48: 1126-1132
        • Nordlinger B.
        • Sorbye H.
        • Glimelius B.
        • et al.
        Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
        Lancet. 2008; 371: 1007-1016
        • Nordlinger B.
        • Sorbye H.
        • Glimelius B.
        • et al.
        Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
        Lancet Oncology. 2013; 14: 1208-1215
        • Gruenberger T.
        • Bridgewater J.
        • Chau I.
        • et al.
        Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
        Annals of Oncology. 2015; 26: 702-708
        • Folprecht G.
        • Gruenberger T.
        • Bechstein W.O.
        • et al.
        Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
        Lancet Oncology. 2010; 11: 38-47
        • Ye L.-C.
        • Liu T.-S.
        • Ren L.
        • et al.
        Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases.
        Journal of Clinical Oncology. 2013; 31: 1931-1938
        • Schmoll H.J.
        • Van Cutsem E.
        • Stein A.
        • et al.
        ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making.
        Annals of Oncology. 2012; 23: 2479-2516
        • Mise Y.
        • Kopetz S.
        • Mehran R.
        • et al.
        Is complete liver resection without resection of synchronous lung metastases justified?.
        Annals of Surgical Oncology. 2015; 22: 1585-1592
        • Goéré D.
        • Deshaies I.
        • de Baere T.
        • et al.
        Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases.
        Annals of Surgery. 2010; 251: 686-691
        • de Gramont A.
        • Van Cutsem E.
        • Schmoll H.-J.
        • et al.
        Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
        Lancet Oncology. 2012; 13: 1225-1233
        • Taieb J.
        • Tabernero J.
        • Mini E.
        • et al.
        Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
        Lancet Oncology. 2014; 15: 862-873
        • Welsh F.K.S.
        • Chandrakumaran K.
        • John T.G.
        • et al.
        Propensity score-matched outcomes analysis of the liver-first approach for synchronous colorectal liver metastases.
        British Journal of Surgery. 2016; 103: 600-606
        • Karoui M.
        • Rullier A.
        • Luciani A.
        • et al.
        Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial – the PRODIGE 22 – ECKINOXE trial.
        BMC Cancer. 2015; 15: 511
        • Berger-Kulemann V.
        • Schima W.
        • Baroud S.
        • et al.
        Gadoxetic acid-enhanced 3.0 T MR imaging versus multidetector-row CT in the detection of colorectal metastases in fatty liver using intraoperative ultrasound and histopathology as a standard of reference.
        European Journal of Surgical Oncology. 2012; 38: 670-676
        • Auer R.C.
        • White R.R.
        • Kemeny N.E.
        • et al.
        Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy.
        Cancer. 2010; 116: 1502-1509
        • Goéré D.
        • Benhaim L.
        • Bonnet S.
        • et al.
        Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy.
        Annals of Surgery. 2013; 257: 114-120
        • Lau K.
        • Salami A.
        • Barden G.
        • et al.
        The effect of a regional hepatopancreaticobiliary surgical program on clinical volume, quality of cancer care, and outcomes in the veterans affairs system.
        JAMA Surgery. 2014; 149: 1153-1161
        • Dindo D.
        • Demartines N.
        • Clavien P.A.
        Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.
        Annals of Surgery. 2004; 240: 205-213
        • Ruers T.
        • Punt C.
        • Van Coevorden F.
        • et al.
        Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004).
        Annals of Oncology. 2012; 23: 2619-2626